Nanoparticles for Glioblastoma Treatment
- PMID: 40574001
- PMCID: PMC12196212
- DOI: 10.3390/pharmaceutics17060688
Nanoparticles for Glioblastoma Treatment
Abstract
GBM is the most common and aggressive primary brain tumor in adults, characterized by low survival rates, high recurrence, and resistance to conventional therapies. Traditional diagnostic and therapeutic methods remain limited due to the difficulty in permeating the blood-brain barrier (BBB), diffuse tumor cell infiltration, and tumor heterogeneity. In recent years, nano-based technologies have emerged as innovative approaches for the detection and treatment of GBM. A wide variety of nanocarriers, including dendrimers, liposomes, metallic nanoparticles, carbon nanotubes, carbon dots, extracellular vesicles, and many more demonstrate the ability to cross the BBB, precisely deliver therapeutic agents, and enhance the effects of radiotherapy and immunotherapy. Surface functionalization, peptide modification, and cell membrane coating improve the targeting capabilities of nanostructures toward GBM cells and enable the exploitation of their photothermal, magnetic, and optical properties. Furthermore, the development of miRNA nanosponge systems offers the simultaneous inhibition of multiple tumor growth mechanisms and the modulation of the immunosuppressive tumor microenvironment. This article presents current advancements in nanotechnology for GBM, with a particular focus on the characteristics and advantages of specific groups of nanoparticles, including their role in radiosensitization.
Keywords: glioblastoma; nanoparticles; radiosensitization; targeted therapy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Breaking Barriers in Glioblastoma Targeting through Advanced Nanoparticle Cell Membrane Coating.ACS Appl Mater Interfaces. 2025 Jun 18;17(24):35288-35303. doi: 10.1021/acsami.5c07306. Epub 2025 Jun 9. ACS Appl Mater Interfaces. 2025. PMID: 40488690 Free PMC article.
-
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.Int J Mol Sci. 2023 Oct 10;24(20):15037. doi: 10.3390/ijms242015037. Int J Mol Sci. 2023. PMID: 37894718 Free PMC article.
-
GRPR-targeted gold nanoparticles as selective radiotherapy enhancers in glioblastoma.Phys Med Biol. 2025 Jun 20;70(12). doi: 10.1088/1361-6560/ade222. Phys Med Biol. 2025. PMID: 40480252
-
Ginsenoside F2-modified liposomes delivering FTY720 enhance glioblastoma targeting and antitumor activity via ferroptosis.Phytomedicine. 2025 Aug;144:156917. doi: 10.1016/j.phymed.2025.156917. Epub 2025 May 30. Phytomedicine. 2025. PMID: 40480023
-
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2. Cochrane Database Syst Rev. 2021. PMID: 34559423 Free PMC article.
References
-
- Pouyan A., Ghorbanlo M., Eslami M., Jahanshahi M., Ziaei E., Salami A., Mokhtari K., Shahpasand K., Farahani N., Meybodi T.E., et al. Glioblastoma multiforme: Insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol. Cancer. 2025;24:58. doi: 10.1186/s12943-025-02267-0. - DOI - PMC - PubMed
-
- Wen P.Y., Weller M., Lee E.Q., Alexander B.M., Barnholtz-Sloan J.S., Barthel F.P., Batchelor T.T., Bindra R.S., Chang S.M., Chiocca E.A., et al. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology. 2020;22:1073–1113. doi: 10.1093/neuonc/noaa106. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources